Geneos Wealth Management’s Pliant Therapeutics PLRX Stock Holding History

Geneos Wealth Management’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,100	Closed	-$53.8K	–	2155
2023 Q3	$53.8K	Hold	3,100	–	–	﹤0.01%	1063
2023 Q2	$56.2K	Hold	3,100	–	–	﹤0.01%	1046
2023 Q1	$82.5K	Hold	3,100	–	–	0.01%	906
2022 Q4	$59.9K	Hold	3,100	–	–	﹤0.01%	984
2022 Q3	$64K	Hold	3,100	–	–	﹤0.01%	943
2022 Q2	$23K	Hold	3,100	–	–	﹤0.01%	1629
2022 Q1	$21K	Hold	3,100	–	–	﹤0.01%	1788
2021 Q4	$41K	Hold	3,100	–	–	﹤0.01%	1561
2021 Q3	$53K	Hold	3,100	–	–	﹤0.01%	1469
2021 Q2	$87K	Hold	3,100	–	–	﹤0.01%	1216
2021 Q1	$103K	Hold	3,100	–	–	﹤0.01%	1299
2020 Q4	$122K	Buy	3,100 +1,600	+107%	+$40.1K	﹤0.01%	1047
2020 Q3	$32K	Buy	+1,500	New	+$37.5K	﹤0.01%	1440

Other funds holding PLRX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Geneos Wealth Management's PLRX Position: Q4 2023 in Review

Geneos Wealth Management sold out of Pliant Therapeutics (PLRX) in Q4 2023, closing a stake of 3,100 shares — an estimated $53.8K sold.

Geneos Wealth Management first reported a position in PLRX in Q3 2020 and held it in 13 quarters. The position peaked at $122K in Q4 2020. 134 funds tracked by Wall St. Rank hold PLRX as of Q4 2023.

Geneos Wealth Management reported no remaining Pliant Therapeutics position as of Q4 2023 after selling out during the quarter.
Geneos Wealth Management sold 3,100 Pliant Therapeutics shares in Q4 2023, an estimated $53.8K.
Geneos Wealth Management first reported a position in Pliant Therapeutics in Q3 2020 and held it in 13 quarters.
Geneos Wealth Management's Pliant Therapeutics position peaked at $122K in Q4 2020.
134 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2023.

Based on Geneos Wealth Management's 13F filing for Q4 2023, filed 26 Jan 2024.